JP2019522680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522680A5 JP2019522680A5 JP2019518186A JP2019518186A JP2019522680A5 JP 2019522680 A5 JP2019522680 A5 JP 2019522680A5 JP 2019518186 A JP2019518186 A JP 2019518186A JP 2019518186 A JP2019518186 A JP 2019518186A JP 2019522680 A5 JP2019522680 A5 JP 2019522680A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antibody
- patient
- binding fragment
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 15
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 4
- WVHGJJRMKGDTEC-WCIJHFMNSA-N 2-[(1R,4S,8R,10S,13S,16S,27R,34S)-34-[(2S)-butan-2-yl]-8,22-dihydroxy-13-[(2R,3S)-3-hydroxybutan-2-yl]-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide Chemical compound CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2 WVHGJJRMKGDTEC-WCIJHFMNSA-N 0.000 claims 4
- 231100000729 Amatoxin Toxicity 0.000 claims 4
- 108010014709 amatoxin Proteins 0.000 claims 4
- 125000000732 arylene group Chemical group 0.000 claims 4
- 125000005549 heteroarylene group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000004419 alkynylene group Chemical group 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- 230000003394 haemopoietic effect Effects 0.000 claims 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000002903 Thalassemia Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000001772 blood platelet Anatomy 0.000 claims 2
- 230000000779 depleting effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000034737 hemoglobinopathy Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 claims 1
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000035809 Lymphohistiocytosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000003651 basophil Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000003593 megakaryocyte Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000001167 myeloblast Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 210000002997 osteoclast Anatomy 0.000 claims 1
- 208000002865 osteopetrosis Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 CC(C)[C@](CO1)OC1=* Chemical compound CC(C)[C@](CO1)OC1=* 0.000 description 2
- JOZQZYKBYAUYOK-YFKPBYRVSA-N CC(C)[C@H](CO1)OC1=O Chemical compound CC(C)[C@H](CO1)OC1=O JOZQZYKBYAUYOK-YFKPBYRVSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022069352A JP2022106807A (ja) | 2016-06-17 | 2022-04-20 | Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351725P | 2016-06-17 | 2016-06-17 | |
| US62/351,725 | 2016-06-17 | ||
| US201662437729P | 2016-12-22 | 2016-12-22 | |
| US62/437,729 | 2016-12-22 | ||
| US201762448782P | 2017-01-20 | 2017-01-20 | |
| US62/448,782 | 2017-01-20 | ||
| PCT/US2017/038158 WO2017219029A2 (en) | 2016-06-17 | 2017-06-19 | Compositions and methods for the depletion of cd117+cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069352A Division JP2022106807A (ja) | 2016-06-17 | 2022-04-20 | Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522680A JP2019522680A (ja) | 2019-08-15 |
| JP2019522680A5 true JP2019522680A5 (enExample) | 2020-07-30 |
| JP7062647B2 JP7062647B2 (ja) | 2022-05-06 |
Family
ID=60119017
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518186A Active JP7062647B2 (ja) | 2016-06-17 | 2017-06-19 | Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法 |
| JP2022069352A Pending JP2022106807A (ja) | 2016-06-17 | 2022-04-20 | Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069352A Pending JP2022106807A (ja) | 2016-06-17 | 2022-04-20 | Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10111966B2 (enExample) |
| EP (1) | EP3472178A4 (enExample) |
| JP (2) | JP7062647B2 (enExample) |
| KR (2) | KR20230066647A (enExample) |
| CN (1) | CN109661400A (enExample) |
| AU (4) | AU2017204125B1 (enExample) |
| BR (1) | BR112018076306A2 (enExample) |
| CA (1) | CA3028134A1 (enExample) |
| IL (2) | IL303455A (enExample) |
| MA (1) | MA45408A (enExample) |
| MX (1) | MX2018015684A (enExample) |
| SG (2) | SG11201811290VA (enExample) |
| WO (1) | WO2017219029A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019522050A (ja) | 2016-06-17 | 2019-08-08 | マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 細胞の枯渇のための組成物および方法 |
| JOP20190155A1 (ar) * | 2016-12-21 | 2019-06-23 | Novartis Ag | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم |
| PT3558390T (pt) | 2016-12-23 | 2024-10-29 | Heidelberg Pharma Res Gmbh | Conjugados amanitina anticorpo |
| US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
| BR112019015342A2 (pt) | 2017-01-30 | 2020-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Regime de condicionamento não genotóxico para o transplante de células-tronco |
| US12485186B2 (en) | 2017-03-31 | 2025-12-02 | The Children's Medical Center Corporation | Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation |
| EP3655534B1 (en) | 2017-07-18 | 2025-07-16 | CSL Behring Gene Therapy, Inc. | Compositions and methods for treating beta-hemoglobinopathies |
| CA3095211A1 (en) * | 2017-09-08 | 2019-03-14 | Sichuan Baili Pharm Co. Ltd | An amantin antibody conjugate |
| CN111601616A (zh) | 2017-10-24 | 2020-08-28 | 美真达治疗公司 | 用于耗尽cd117+细胞的组合物和方法 |
| JP7280254B2 (ja) | 2017-10-24 | 2023-05-23 | マジェンタ セラピューティクス インコーポレイテッド | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
| KR20200094181A (ko) * | 2017-11-29 | 2020-08-06 | 마젠타 테라퓨틱스 인코포레이티드 | Cd5+ 세포를 고갈시키기 위한 조성물 및 방법 |
| US12133884B2 (en) | 2018-05-11 | 2024-11-05 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| AU2019283654A1 (en) * | 2018-06-07 | 2021-01-28 | Vor Biopharma, Inc. | Therapeutic methods using antibody drug conjugates (ADCs) |
| TW202014209A (zh) * | 2018-06-20 | 2020-04-16 | 瑞士商諾華公司 | 用於消融造血幹細胞之抗體藥物軛合物 |
| AU2019312200B2 (en) * | 2018-07-23 | 2024-11-14 | Heidelberg Pharma Research Gmbh | Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy |
| JP2021535092A (ja) * | 2018-08-13 | 2021-12-16 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | 結合体およびその使用方法 |
| WO2020092655A1 (en) * | 2018-10-30 | 2020-05-07 | Magenta Therapeutics, Inc. | Methods for allogeneic hematopoietic stem cell transplantation |
| CR20210272A (es) * | 2018-11-26 | 2021-07-14 | Forty Seven Inc | Anticuerpos humanizados contra c-kit |
| WO2020139796A1 (en) | 2018-12-23 | 2020-07-02 | Csl Behring L.L.C. | Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome |
| JP2022530443A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | 抗ｃｄ１１７抗体薬物複合体およびその使用 |
| EP3958909A4 (en) * | 2019-04-24 | 2024-01-10 | Magenta Therapeutics, Inc. | Anti-cd117 antibody-drug conjugates and uses thereof |
| EP3959243A4 (en) * | 2019-04-24 | 2023-04-12 | Magenta Therapeutics, Inc. | ANTI-CD117 ANTIBODIES AND USES THEREOF |
| WO2020219774A1 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anthracycline antibody-drug conjugates and uses thereof |
| CA3134689A1 (en) * | 2019-04-24 | 2020-10-29 | Anthony Boitano | Conditioning methods for gene therapy |
| CA3146912A1 (en) * | 2019-07-09 | 2021-01-14 | Hemogenyx Pharmaceuticals Llc | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies |
| BR112022002953A2 (pt) * | 2019-08-29 | 2022-05-17 | Beam Therapeutics Inc | Composições e métodos para condicionamento não tóxico |
| WO2022081828A1 (en) * | 2020-10-16 | 2022-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hematopoietic stem cell engraftment with a combination of agents |
| WO2022099083A1 (en) * | 2020-11-06 | 2022-05-12 | Bluebird Bio, Inc. | Methods |
| CN113485489B (zh) * | 2021-06-18 | 2022-05-10 | 淮阴工学院 | 一种orc系统蒸发器出口温度的调控方法 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451575A (en) | 1988-02-19 | 1995-09-19 | J. W. Broadbent Nominees Pty., Ltd. | Method of treating liver dysfunction with 24-R scymnol |
| AU5186090A (en) | 1989-02-23 | 1990-09-26 | Colorado State University Research Foundation | Gnrh analogs for destroying gonadotrophs |
| US5786457A (en) | 1989-02-23 | 1998-07-28 | Colorado State University Research Foundation | Hormone-nuclease compounds and method for regulating hormone related diseases |
| US5273738A (en) | 1990-03-03 | 1993-12-28 | Fred Hutchinson Cancer Research Center | Radiation delivery to lymphoid and marrow tissues |
| US5367057A (en) | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
| ATE169031T1 (de) | 1991-04-05 | 1998-08-15 | Univ Washington | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor |
| WO1993015751A1 (en) | 1992-02-14 | 1993-08-19 | Merck & Co., Inc. | CHIMERIC TOXINS BINDING TO THE GnRH RECEPTOR |
| WO1994025621A1 (en) | 1993-04-30 | 1994-11-10 | Lxr Biotechnology Inc. | Methods of identifying potentially therapeutically effective agents and cell strains for use therein |
| US6024957A (en) | 1993-06-02 | 2000-02-15 | Research Corporation Technologies, Inc. | Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same |
| US6106834A (en) | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
| ES2269266T3 (es) | 1993-09-08 | 2007-04-01 | Imclone Systems, Inc. | Anticuerpos monoclonales que reconocen los receptores de flk-2 y el aislamiento de poblaciones de celulas madre hematopoyeticas primitivas. |
| GB2282812A (en) | 1993-10-15 | 1995-04-19 | Merck & Co Inc | Cytotoxic/receptor ligand conjugates linked via lysine radicals |
| GB9323199D0 (en) | 1993-11-10 | 1994-01-05 | Falkenberg J H F | Leukaemia treatment |
| DE4343261C2 (de) | 1993-12-17 | 1995-11-02 | Susanne Holzer | Verfahren zur präparativen Herstellung von Ausgangsstoffen für Immunoassays und Bioassays |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| DE19600589C1 (de) | 1996-01-10 | 1997-01-16 | Univ Eberhard Karls | Antikörper A3C6E2 |
| DE19608769C1 (de) | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
| CA2268340A1 (en) | 1996-10-11 | 1998-04-23 | Bristol-Myers Squibb Company | Methods and compositions for immunomodulation |
| AU6954398A (en) | 1997-04-11 | 1998-11-11 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
| DE19727814C1 (de) | 1997-06-30 | 1998-10-01 | Univ Eberhard Karls | Anitkörper 4G8B4B12 |
| DE19808453C2 (de) | 1998-02-27 | 2000-12-14 | Gsf Forschungszentrum Umwelt | Expressionsvektor zur konditionalen Regulation der Expression der großen Untereinheit der RNA-Polymerase II |
| US6339062B1 (en) | 1998-11-23 | 2002-01-15 | Inkine Pharmaceutical Company, Inc. | Retroinverso polypeptides that mimic or inhibit thrombospondin activity |
| AU2951599A (en) | 1999-04-08 | 2000-11-14 | Pavel Sergeev | Synthesis of biologically active compounds in cells |
| US6159443A (en) | 1999-04-29 | 2000-12-12 | Vanderbilt University | X-ray guided drug delivery |
| AUPQ014699A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using nanoparticles |
| AUPQ014799A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
| AU4985201A (en) | 2000-10-18 | 2002-04-29 | Us Gov Health & Human Serv | Human gene critical to fertility |
| JP2004536555A (ja) | 2000-11-03 | 2004-12-09 | ダナ ファーバー キャンサー インスティテュート | 癌感受性の診断のための方法及び組成物並びに欠損ｄｎａ修復メカニズム及びその処置 |
| US20050069538A1 (en) | 2003-09-18 | 2005-03-31 | Gregorio Aversa | Therapeutic binding molecules |
| GB0110430D0 (en) | 2001-04-27 | 2001-06-20 | Medical Res Council | Protein variants and uses thereof |
| GB0122914D0 (en) | 2001-09-22 | 2001-11-14 | Univ Nottingham | Modulation of stat activity |
| CN1184890C (zh) | 2001-10-09 | 2005-01-19 | 湖南师范大学 | 含鹅膏肽毒素基因的苏云金杆菌工程菌双效杀虫剂 |
| WO2003048327A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection |
| AR037756A1 (es) | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
| US7183385B2 (en) | 2002-02-20 | 2007-02-27 | Cell Signaling Technology, Inc. | Phospho-specific antibodies to Flt3 and uses thereof |
| US20030232369A1 (en) | 2002-04-17 | 2003-12-18 | Bushnell David A. | Molecular structure of RNA polymerase II |
| DE10219866A1 (de) | 2002-05-03 | 2003-11-20 | Isolde Riede-Kainrath | Tumorprävention und Therapie durch Modifikation von "switch"-Genen oder RNA-Polymerase II-Aktivität |
| AU2003245752A1 (en) * | 2002-06-28 | 2004-01-19 | Bio Transplant, Inc. | Process for promoting graft acceptance by depletion of hematopoietic stem cells |
| AU2002953073A0 (en) | 2002-11-21 | 2003-01-16 | Access Pharmaceuticals Australia Pty Limited | Amplification of biotin-mediated targeting |
| US7166691B2 (en) | 2002-12-20 | 2007-01-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Saposin C and receptors as targets for treatment of benign and malignant disorders |
| WO2006002064A2 (en) | 2004-06-14 | 2006-01-05 | Aerovance, Inc. | Antibody inhibiting stem cell factor activity and use for treatment of asthma |
| US20060014197A1 (en) | 2004-07-15 | 2006-01-19 | Wisconsin Alumni Research Foundation | In vivo screening methods for identifying inhibitors of RNA polymerases |
| AU2005274852B2 (en) | 2004-07-19 | 2011-12-08 | The Johns Hopkins University | FLT3 inhibitors for immune suppression |
| EP1661584A1 (en) | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
| WO2006127978A2 (en) | 2005-05-24 | 2006-11-30 | Dana Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| WO2007080114A2 (en) | 2006-01-11 | 2007-07-19 | Biotech Igg Ab | Macromolecule conjugate |
| WO2007092196A2 (en) | 2006-01-27 | 2007-08-16 | Cellerant Therapeutics, Inc. | Compositions and methods for treating myeloid proliferative disorders |
| CA2649114A1 (en) | 2006-04-12 | 2007-10-25 | Crosslink Genetics Corporation | Compositions and methods for modulating gene expression |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| ATE521366T1 (de) | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
| PL3255061T3 (pl) * | 2006-11-03 | 2021-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia |
| US20100093008A1 (en) | 2007-03-02 | 2010-04-15 | Cell Signaling Technology, Inc. | Phospho-specific antibodies to flt3 (tyr969) and uses thereof |
| EP3569251A1 (en) | 2007-06-25 | 2019-11-20 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| CA2694983A1 (en) | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Treatments of b-cell proliferative disorders |
| US9518097B2 (en) | 2007-11-09 | 2016-12-13 | Board Of Trustees Of Michigan State University | Identification and use of genes encoding amatoxin and phallotoxin |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| WO2010045218A1 (en) | 2008-10-13 | 2010-04-22 | Board Of Regents, The University Of Texas System | Molecular clock mechanism of hybrid vigor |
| US8940705B2 (en) | 2009-01-09 | 2015-01-27 | The Regents Of The University Of California | Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone |
| EP2416805B1 (en) * | 2009-04-08 | 2013-07-24 | Heinz Dr. Faulstich | Amatoxin antibody conjugates for the treatment of cancer |
| EP3192529B1 (en) * | 2009-04-08 | 2020-03-25 | Faulstich, Heinz, Dr. | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
| US20120253017A1 (en) * | 2009-05-28 | 2012-10-04 | Victoria Ballard | Stem cell targeting |
| JP6114936B2 (ja) * | 2009-08-31 | 2017-04-19 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 強力な細胞毒性活性を示すランピルナーゼ（ｒａｐ）を含む免疫毒素の組成物及び使用方法 |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| EP2516652B1 (en) | 2009-12-21 | 2014-11-05 | Keygene N.V. | Improved techniques for transfecting protoplasts |
| US9023996B2 (en) | 2009-12-23 | 2015-05-05 | Synimmune Gmbh | Anti-FLT3 antibodies |
| HUE045270T2 (hu) | 2010-01-05 | 2019-12-30 | Inst Nat Sante Rech Med | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére |
| KR20110085038A (ko) | 2010-01-19 | 2011-07-27 | 울산대학교 산학협력단 | 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법 |
| CN101861796B (zh) | 2010-05-18 | 2012-02-15 | 四川大学 | 一种利用有色稻米发酵废糟培养豹斑毒鹅膏的方法 |
| AU2011312776B2 (en) | 2010-07-13 | 2016-09-29 | University Of Rhode Island Board Of Trustees | Environmentally sensitive compositions |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| ES2402254T3 (es) | 2010-09-30 | 2013-04-30 | Heidelberg Pharma Ag | Conjugados de amatoxinas con ligadores mejorados |
| WO2012084895A2 (en) | 2010-12-20 | 2012-06-28 | Universiteit Gent | Crystal structure of flt3 ligand-receptor complex |
| CN102526034B (zh) | 2010-12-24 | 2015-02-25 | 四川大学华西医院 | 恒河猴爆发性肝功能衰竭模型的建立 |
| US20150018408A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
| AR085091A1 (es) | 2011-01-26 | 2013-09-11 | Kolltan Pharmaceuticals Inc | Anticuerpos anti-kit y sus usos |
| EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
| AR086044A1 (es) * | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| WO2013131927A1 (en) | 2012-03-06 | 2013-09-12 | Novartis Ag | Combining dna-damaging agents and modulators of actin polymerization for the treatment of cancer |
| EP2849797B1 (en) | 2012-05-15 | 2019-12-18 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
| US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| EP2684865A1 (en) * | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
| CN102786586A (zh) | 2012-07-20 | 2012-11-21 | 包海鹰 | 玫瑰红鹅膏发酵菌丝体中肽类毒素的发现 |
| SG11201500489YA (en) | 2012-07-25 | 2015-02-27 | Kolltan Pharmaceuticals Inc | Anti-kit antibodies and uses thereof |
| WO2014043403A1 (en) | 2012-09-12 | 2014-03-20 | Agensys, Inc. | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
| BR112015006368B1 (pt) | 2012-09-24 | 2022-02-08 | Medimmune Limited | Processo para produção de linha celular eucariótica estável |
| GB201217296D0 (en) | 2012-09-27 | 2012-11-14 | Alta Innovations Ltd | Method of treatment and/or prevention |
| HK1212618A1 (zh) | 2012-10-16 | 2016-06-17 | 恩多塞特公司 | 含有非天然氨基酸的藥物遞送綴合物以及其使用方法 |
| JP6441232B2 (ja) | 2012-12-27 | 2018-12-19 | サノフイＳａｎｏｆｉ | 抗ｌａｍｐ１抗体および抗体薬物コンジュゲート、ならびにその使用 |
| EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
| MX366978B (es) | 2013-03-15 | 2019-08-01 | Novartis Ag | Conjugados de anticuerpo - farmaco. |
| WO2014151030A1 (en) * | 2013-03-15 | 2014-09-25 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| US10071170B2 (en) | 2013-06-24 | 2018-09-11 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
| FR3008408B1 (fr) * | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| JP6439690B2 (ja) | 2013-07-12 | 2018-12-19 | 石原産業株式会社 | 細胞への遺伝子導入用組成物 |
| ES2800602T3 (es) | 2013-07-23 | 2021-01-04 | Ohio State Innovation Foundation | Procedimientos y composiciones relacionados con los fragmentos de anticuerpos monocatenarios que se unen a la glucoproteína 72 asociada a tumor (TAG-72) |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| JP6441949B6 (ja) | 2013-11-05 | 2019-01-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ヒト中和抗ｋｉｔ抗体及びその使用 |
| CN103627757B (zh) | 2013-12-02 | 2016-04-13 | 云南大学 | 提高小豹斑鹅膏菌丝体产毒能力的方法 |
| CN105377304B (zh) * | 2014-03-10 | 2018-05-15 | 海德堡医药有限责任公司 | 鹅膏毒肽衍生物 |
| EP3129407A2 (en) | 2014-03-12 | 2017-02-15 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| EP3783034A1 (en) | 2014-07-23 | 2021-02-24 | Ohio State Innovation Foundation | Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72) |
| ES2945588T3 (es) | 2014-08-26 | 2023-07-04 | Univ Leland Stanford Junior | Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora |
| WO2016036334A1 (en) | 2014-09-03 | 2016-03-10 | Şahi̇n Yücel | Voltametric methods to determine alpha-amanitin and phalloidin |
| EP3207048A4 (en) | 2014-10-17 | 2018-05-30 | The Broad Institute, Inc. | Compositions and methods of treating muscular dystrophy |
| WO2016071856A1 (en) | 2014-11-06 | 2016-05-12 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
| EA201790871A1 (ru) | 2014-11-11 | 2017-11-30 | Амуникс Оперэйтинг Инк. | Нацеленные конъюгатные композиции xten и способы их получения |
| US20160220687A1 (en) | 2015-02-02 | 2016-08-04 | National Guard Health Affairs | Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer |
| KR20240091253A (ko) | 2015-02-16 | 2024-06-21 | 론자 리미티드 | Cl 및/또는 ch1 돌연변이된 약물 접합용 항체 |
| DK3265565T3 (da) | 2015-03-04 | 2020-11-09 | Univ Texas | Fremgangsmåder til behandling af cancer, som har hemizygot tab af tp53 |
| US9974865B2 (en) | 2015-03-09 | 2018-05-22 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to FLT3 proteins |
| PT3268047T (pt) | 2015-03-09 | 2023-12-05 | Heidelberg Pharma Res Gmbh | Conjugados amatoxina-anticorpo |
| WO2016145014A1 (en) | 2015-03-10 | 2016-09-15 | President And Fellows Of Harvard College | Methods for treatment of autism spectrum disorders |
| WO2016154588A1 (en) | 2015-03-25 | 2016-09-29 | Children's Hospital Medical Center | Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation |
| WO2016164502A1 (en) * | 2015-04-06 | 2016-10-13 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
| US10683506B2 (en) | 2015-04-10 | 2020-06-16 | The Methodist Hospital System | CD117 ligand-drug conjugates for targeted cancer therapy |
| WO2016168471A1 (en) | 2015-04-17 | 2016-10-20 | Endocyte, Inc. | Dual disulfide drug conjugates |
| CN104862314B (zh) | 2015-05-11 | 2017-12-01 | 昆明理工大学 | 一种与α‑鹅膏毒肽特异结合的核酸适配体及应用 |
| EP3297647A1 (en) | 2015-05-18 | 2018-03-28 | Universidade Do Porto | Use of polymyxin as an antidote for intoxications by amatoxins |
| US10806808B2 (en) | 2015-05-22 | 2020-10-20 | Memorial Sloan Kettering Cancer Center | Systems and methods for determining optimum patient-specific antibody dose for tumor targeting |
| EP3954394A1 (en) | 2015-06-19 | 2022-02-16 | Centurion BioPharma Corporation | Delivery systems for controlled drug release |
| WO2017004127A1 (en) | 2015-06-29 | 2017-01-05 | The General Hospital Corporation | Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion |
| JP2018523471A (ja) | 2015-07-16 | 2018-08-23 | セレラント セラピューティクス インコーポレイテッド | システイン置換免疫グロブリン |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| US10660954B2 (en) | 2015-07-31 | 2020-05-26 | University Of Florida Research Foundation, Incorporated | Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer |
| CN105177009B (zh) | 2015-08-10 | 2018-05-25 | 昆明理工大学 | 一种与α-鹅膏毒肽特异结合的核酸适配体及应用 |
| CA3013412C (en) | 2016-02-04 | 2023-10-10 | Suzhou M-Conj Biotech Co., Ltd. | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
| CN106153768B (zh) | 2016-06-30 | 2019-01-01 | 佛山科学技术学院 | 鹅膏毒肽分子印迹材料用于α-amanitin和β-amanitin的固相萃取方法 |
| JOP20190155A1 (ar) * | 2016-12-21 | 2019-06-23 | Novartis Ag | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم |
-
2017
- 2017-06-19 US US15/626,910 patent/US10111966B2/en active Active
- 2017-06-19 AU AU2017204125A patent/AU2017204125B1/en not_active Ceased
- 2017-06-19 IL IL303455A patent/IL303455A/en unknown
- 2017-06-19 MX MX2018015684A patent/MX2018015684A/es unknown
- 2017-06-19 WO PCT/US2017/038158 patent/WO2017219029A2/en not_active Ceased
- 2017-06-19 SG SG11201811290VA patent/SG11201811290VA/en unknown
- 2017-06-19 KR KR1020237014621A patent/KR20230066647A/ko not_active Ceased
- 2017-06-19 IL IL263744A patent/IL263744B2/en unknown
- 2017-06-19 SG SG10202100726XA patent/SG10202100726XA/en unknown
- 2017-06-19 KR KR1020197001540A patent/KR20190038537A/ko not_active Ceased
- 2017-06-19 JP JP2019518186A patent/JP7062647B2/ja active Active
- 2017-06-19 MA MA045408A patent/MA45408A/fr unknown
- 2017-06-19 CA CA3028134A patent/CA3028134A1/en active Pending
- 2017-06-19 EP EP17814263.4A patent/EP3472178A4/en active Pending
- 2017-06-19 BR BR112018076306-3A patent/BR112018076306A2/pt not_active IP Right Cessation
- 2017-06-19 CN CN201780050606.8A patent/CN109661400A/zh active Pending
-
2018
- 2018-01-22 AU AU2018200503A patent/AU2018200503C1/en not_active Ceased
- 2018-10-11 US US16/158,164 patent/US20190134217A1/en not_active Abandoned
-
2020
- 2020-02-18 AU AU2020201138A patent/AU2020201138A1/en not_active Abandoned
-
2021
- 2021-02-10 US US17/173,119 patent/US20210162063A1/en active Pending
-
2022
- 2022-04-04 AU AU2022202233A patent/AU2022202233A1/en not_active Abandoned
- 2022-04-20 JP JP2022069352A patent/JP2022106807A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522680A5 (enExample) | ||
| ES2649155T3 (es) | Anticuerpos anti-OX40 y procedimientos de uso de los mismos | |
| JP2019522050A5 (enExample) | ||
| CN110461876B (zh) | 用于耗尽cd137+细胞的组合物和方法 | |
| ES2964168T3 (es) | Anticuerpo anti-interleucina 22 (IL-22) y usos del mismo | |
| ES2954183T3 (es) | Anticuerpo humanizado o fragmento de este específico para CD3 | |
| JP6862435B2 (ja) | 抗ｗｔ１／ｈｌａ特異的抗体 | |
| ES2824767T3 (es) | Anticuerpos anti-CD4 modificados | |
| JP2021500391A5 (enExample) | ||
| KR20230066647A (ko) | Cd117+ 세포의 고갈을 위한 조성물 및 방법 | |
| ES2384466T3 (es) | Composiciones y procedimientos de tratamiento de una infección viral | |
| KR20230082055A (ko) | 세포의 고갈을 위한 조성물 및 방법 | |
| UA125382C2 (uk) | Антитіла проти людського vista та їх застосування | |
| WO2019108863A4 (en) | Compositions and methods for the depletion of cd5+ cells | |
| JP2014520092A5 (enExample) | ||
| CN109963590A (zh) | 涉及白介素-6受体α结合单链可变片段的方法和组合物 | |
| ES2737307T3 (es) | Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer | |
| JP2020007318A5 (enExample) | ||
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| ES2865735T3 (es) | Anticuerpo anti-hmgb1 humanizado o fragmento de unión a antígeno del mismo | |
| CN107922938A (zh) | 抗体 | |
| CN104105706A (zh) | 用于治疗疾病的抗人sema4A抗体 | |
| AU2018370120A1 (en) | Methods for selective expansion of d3 yd T-cell populations and compositions thereof | |
| WO2018034597A1 (ru) | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека | |
| ES2936075T3 (es) | Activador de células T reguladoras, y uso del mismo |